TitleApplication of shRNA-containing herpes simplex virus type 1 (HSV-1)-based gene therapy for HSV-2-induced genital herpes
AuthorsLiu, Zhihong
Xiang, Yang
Wei, Zhun
Yu, Bo
Shao, Yong
Zhang, Jie
Yang, Hong
Li, Manmei
Guan, Ming
Wan, Jun
Zhang, Wei
AffiliationPeking Univ, Shenzhen Hosp, Dept Obstet & Gynecol, Shenzhen 518036, Guangdong, Peoples R China.
Shenzhen PKU HKUST Med Ctr, Biomed Res Inst, Shenzhen 518036, Guangdong, Peoples R China.
Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China.
Shenzhen PKU HKUST Med Ctr, Shenzhen Key Lab Translat Med Dermatol, Shenzhen 518036, Guangdong, Peoples R China.
Peking Univ, Shenzhen Hosp, Shenzhen Key Discipline Dermatol, Shenzhen 518036, Guangdong, Peoples R China.
Peking Univ, Shenzhen Hosp, Dept Dermatol, Shenzhen 518036, Guangdong, Peoples R China.
Peking Univ, Shenzhen Hosp, Dept Clin Lab, Shenzhen 518036, Guangdong, Peoples R China.
Ji Nan Univ, Coll Pharm, JNU HKUST Joint Lab, Jinan, Guangdong, Peoples R China.
Fudan Univ, Huashan Hosp, Cent Lab, Dept Lab Med, Shanghai 200040, Peoples R China.
Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China.
Shenzhen PKU HKUST Med Ctr, Shenzhen Key Lab Translat Med Dermatol, Biomed Res Inst, 1120 Lianhua Rd, Shenzhen 518036, Guangdong, Peoples R China.
KeywordsHerpes simplex virus type 1 (HSV-1) vector
Herpes simplex virus type 2 (HSV-2)
Genital herpes
IMMUNOGENICITY
GLYCOPROTEINS
PROTECTION
INFECTION
IMMUNITY
NEURONS
HSV-2
MODEL
MICE
Issue Date2013
Publisher病毒学方法杂志
CitationJOURNAL OF VIROLOGICAL METHODS.2013,193,(2),353-358.
AbstractHSV-1-based vectors have been widely used to achieve targeted delivery of genes into the nervous system. In the current study, we aim to use shRNA-containing HSV-1-based gene delivery system for the therapy of HSV-2 infection. Guinea pigs were infected intravaginally with HSV-2 and scored daily for 100 days for the severity of vaginal disease. HSV-2 shRNA-containing HSV-1 was applied intravaginally daily between 8 and 14 days after HSV-2 challenge. Delivery of HSV-2 shRNA-containing HSV-1 had no effect on the onset of disease and acute virus shedding in animals, but resulted in a significant reduction in both the cumulative recurrent lesion days and the number of days with recurrent disease. Around half of the animals in the HSV-2 shRNA group did not develop recurrent disease 100 days post HSV-2 infection. In conclusion, HSV-2 shRNA-containing HSV-1 particles are effective in reducing the recurrence of genital herpes caused by HSV-2. (C) 2013 Elsevier B.V. All rights reserved.
URIhttp://hdl.handle.net/20.500.11897/190466
ISSN0166-0934
DOI10.1016/j.jviromet.2013.06.037
IndexedSCI(E)
PubMed
Appears in Collections:深圳医院

Web of Science®



Checked on Last Week

Scopus®



Checked on Current Time

百度学术™



Checked on Current Time

Google Scholar™





License: See PKU IR operational policies.